Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company’s lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate. STSA $6.8400 -0.4800 % -6.5600 Satsuma Pharmaceuticals Inc Sector : Medical Industry : Medical – Biomedical Signal Short Term Trend […]
Read MoreAkero Therapeutics, Inc. (AKRO) Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company’s lead product candidate is efruxifermin (EFX). Brainstorm Cell Therapeutics Inc. (BCLI) Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of […]
Read MoreEve Holding, Inc. (EVEX) Eve Holding, Inc. develops urban air mobility solutions. It is involved in the design and production of eVTOLs; provision of eVTOL service and support capabilities, including material services, maintenance, technical support, training, ground handling, and data services. Teekay Tankers Ltd. (TNK) Teekay Tankers Ltd. provides marine transportation services to oil industries […]
Read MoreBuy Price: $14.85 or better Sell Price: TradersPro Sell Signal FREYR Battery engages in the production and sale of battery cells for stationary energy storage, electric mobility, and marine applications in Europe and internationally. The company designs and manufactures lithium-ion based battery cell facilities. The company was founded in 2018 and is based in Luxembourg. […]
Read MoreStocks in the Technology sector get a lot of attention and buzz from investors, analysts and talking heads alike no matter the time of year or current status of the economy. A big reason comes from the reality that progress, innovation and evolution in just about every other sector of the economy is driven by […]
Read More(Bloomberg) — The great tech selloff of 2022 is far from over as investors brace for earnings misses that may spur a more than 10% plunge in the Nasdaq 100. More than two-thirds of 914 respondents in the MLIV Pulse survey think profits of the technology companies will disappoint the market throughout 2022. Firms including […]
Read More